1. Introduction {#sec1-1}
===============

Tardive dyskinesia (TD) is a delayed and persistent abnormal involuntary movement disorder which occurs after patients' long-term use of antipsychotic medication. Often TD begins to appear 1 to 2 years after patients begin antipsychotic medication. Among patients with schizophrenia, the life quality of patients with TD drops to 12.3%, compared to patients without TD.^\[[@ref1]\]^ This leads to a decrease in patients' social functioning, and has been shown to affect quality of life and medication compliance significantly.^\[[@ref2]\]^ In addition secondary conditions such as TD can increase the difficulty in treating the primary illness, thereby increasing the financial burden on the patient's family.

TD can present in a variety of ways. Early clinical symptoms are mainly disordered movements in the mouth, tongue and facial areas, which appear as repetitive and uncontrollable. TD symptoms can also affect movement of limbs, head, neck and torso, and patients with severe conditions may also suffer from unclear articulation, difficulty swallowing, and abnormal postures.^\[[@ref3],\ [@ref4]\]^ In addition, some patients may have gastrointestinal tardive dyskinesia which causes symptoms, such as discomfort in the stomach, nausea and vomiting. TD can present with numerous different disordered movements involving many areas of the body and there can also be great variation in presentation among different individuals. It is not uncommon to see TD during the course of clinical work, nevertheless we do not have a deep understanding of this disorder due to its unclear etiology, numerous clinical symptoms, multiple affected areas and wide variation in presentation across individuals. In China and other low and middle income countries there is also a lack of mental health resources resulting in a higher medical staff to patient ratio. In clinical practice this can result in less time available for each individual patient and therefore a later recognition and diagnosis of TD. In the meantime, there has until now not been any effective treatment for TD found; so it affects patients' life quality significantly and aggravates their economic and social burden. Hence, understanding the relationship between movement patterns, clinical characteristics, use of antipsychotic medications, psychotic symptoms and movement disorders is vital to recognizing TD in its early stages and providing timely interventions. The present study aims to explore the questions listed above and provide clinical data useful for the diagnosis and treatment of TD.

2. Methods {#sec1-2}
==========

2.1 Participants {#sec2-1}
----------------

Participants were recruited from among psychiatric inpatients at the Xuhui Mental Health Center in Shanghai, China. Inclusion criteria were the following: (1) participants aged between 20 and 70; (2) diagnosed by two experienced psychiatrists as having schizophrenia according to the criteria of the International Classification of Diseases and Related Health Problems, 10th edition (ICD-10) ^\[[@ref5]\]^; (3) total duration of illness of schizophrenia being equal to or over one year; (4) duration of taking antipsychotic medication being equal to or over one year; (5) patients who were able to complete all the scales and sign written consent forms, or whose guardians could provide signed consent forms. Exclusion criteria: (1) patients with other comorbid severe medical conditions; (2) patients who had comorbid neurological diseases; (3) patients with incomplete medical records or scales; (4) patients who were not able to cooperate with the protocol of the study. We classified patients as having TD according to the the diagnostic criteria of TD developed by Schooler and Kane.^\[[@ref7]\]^ Those patients who did not have TD were classified as the non-TD group. Within the TD group, participants were divided into two groups based on their affected movement patterns (i.e. those with a single area movement disorder and those with movement disorder in multiple areas). All participants provided consent to participate in this study. This study was approved by the ethics committee of the Shanghai Xuhui Mental Health Center.

2.2 Research methods {#sec2-2}
--------------------

### 2.2.1 Basic clinical information {#sec3-1}

Clinical information collected was the following: gender, age, date of the present hospitalization, total duration of illness, and antipsychotic medication use (i.e., types of medication used, treatment type such as single-drug or multiple-drug use, etc), and antipsychotic medication dosage (unified conversion to chlorpromazine equivalent). ^\[[@ref6]\]^

### 2.2.2 Evaluation of psychotic symptoms {#sec3-2}

Positive and Negative Syndrome Scale (PANSS) was used to carry out evaluation of the participants. The severity of patients' psychotic symptoms were reflected by positive symptom factor scores, negative symptom factor scores, general psychopathological scale factor scores and the total scores of PANSS.

### 2.2.3 Diagnostic tools and evaluation of TD {#sec3-3}

According to the research diagnostic criteria of TD developed by Schooler and Kane,^\[[@ref7]\]^ patients whose symptoms had been present for over 3 months and had one sub-score of 3 or higher in the Abnormal Involuntary Movement Scale (AIMS), or two sub-scores of 2 or higher in AIMS met criteria for TD. In addition, patients whose abnormal involuntary movements were induced by infections, seizure, Parkinson's disease and other diseases were excluded; and patients with brain diseases were also excluded. This scale has five rankings for the severity of abnormal movements and the loss of movement ability caused by abnormal movements: 0 = none; 1 = minimal; 2 = mild; 3 = moderate; 4 = severe. Patients' self-awareness towards abnormal movement were also rated on a five point scale: 0 = not aware; 1 = aware, no distress; 2 = aware, mild distress; 3 = aware, moderate distress; 4 = aware, severe distress.

### 2.2.4 TD abnormal movement pattern analysis {#sec3-4}

For participants in this study, the areas affected and the characteristics of symptoms were recorded, and the severity of TD symptoms, loss of movement ability and self-awareness surrounding the disease were evaluated.

2.3 Statistics {#sec2-3}
--------------

SPSS 19.0 was used to analyze data. Count data were represented with percentage (%), and were analyzed using *χ2* tests. Measurement data were represented with mean (standard deviation); data which met normal distribution were analyzed with ANOVA, while data which met non-normal distribution were analyzed with nonparametric tests. Ranked data were also analyzed with nonparametric tests. If the results of ANOVA were significant (p\<0.05), the OR values of the factors were calculated with Logistic regression analyses to estimate the influences these factors had on TD. Two-sided tests were employed in all statistical tests, and the value of *p* being less than 0.05 indicated statistically significant differences.

3. Results {#sec1-3}
==========

3.1 Comparisons between TD group and non-TD group {#sec2-4}
-------------------------------------------------

Six hundred and eighty-two inpatients were screened at the Xuhui Mental Health Center (Shanghai, China), and four hundred and forty-eight patients met the inclusion criteria for chronic schizophrenia (300 males and 148 females). Forty-six of the participants were classified as having TD (36 males and 10 females). There were 402 patients in the non-TD group (264 males and 138 females). There was a significant difference in gender between the TD group and the non-TD group (*p*=0.028, *χ2*=4.81). The mean (sd) age of the TD group was 57.8 (8.5) years old, while that of the non-TD group was 44.8 (13.0) years old; there was also a significant difference in age between the two groups (*p*\<0.001, *f*=36.42). The mean total duration of illness of schizophrenia in the TD group was 32.8 (10.2) years, while that in the control group was 26.5 (6.1) years; the difference between two groups was significant (*p*\<0.001, *f*=17.59). As for the age of onset, the mean (sd) age of the TD group was 18.0 (12.5) years old, while that of the non-TD group was 24.8 (6.0) years old; the two groups' mean age of onset were significantly different from each other (*p*=0.001, *f*=11.99). In terms of the dose of antipsychotic medication (daily chlorpromazine equivalent), the mean (sd) dose for the TD group was 573.1 (228.6) mg/d, whereas that of the non-TD group was 447.4 (188.9) mg/d; the difference between two groups was significantly different (*p*=0.001, *f*=10.60). There were no significant differences between the two groups in the medication-taking method (i.e., single-drug or multiple-drug). As for the scores on the PANSS, the total scores and the negative symptom factor scores of TD group were significantly greater than those of the control group (the total score: *p*=0.009, *f*=6.98; the negative factor score: *f*=13.91). There were no significant differences in the positive symptom factor scores and the general psychopathological scale factor scores between two groups. See [Table 1](#table001){ref-type="table"}.

3.2 Comparisons of the affected areas in patients with TD {#sec2-5}
---------------------------------------------------------

The movement disorder caused by TD in patients with chronic schizophrenia affected the following areas: facial and oral areas, limbs and torsos. There were 31 participants who were affected in the facial and oral areas (12 of them were affected in a single area, and 19 of them were affected in multiple areas). Twenty-seven participants were affected in their limbs (7 of them were affected in a single area, and 20 of them were affected in multiple areas). There were 17 participants who were affected in their torsos (2 of them were affected in a single area, and 15 of them were affected in multiple areas). There were significant differences among the movement disorder's rates of occurrence in different body areas (*p*=0.011, *χ2*=9.11), and their corresponding AIMS sub-scale scores were also significantly different (*p*\<0.001, *χ2*=9.98). See [Table 3](#table003){ref-type="table"}.

3.3 Comparisons between TD patients with a single affected area and those with multiple affected areas {#sec2-6}
------------------------------------------------------------------------------------------------------

Within the TD group, there were 21 participants who had a single affected area, while 25 participants had multiple affected areas. There were 16 males and 5 females in the group of TD patients with a single affected area, and there were 20 males and 5 females in the group of TD patients with multiple affected areas. There was a significant difference in gender between these two TD groups (*p*=0.004, *χ2*=8.37). The mean (sd) age of onset of schizophrenia in TD patients with multiple affected areas (22.38 (4.72)) was significantly smaller than that in TD patients with a single affected area (26.88 (6.24)) (*p*=0.009, *χ2*=7.37). These two TD groups had no significant differences in age, total duration of illness, the medication-taking methods (single-drug or multiple-drug), and dose of antipsychotic medication (daily chlorpromazine equivalent).

According to the results of AIMS, the total scores of participants with a single affected area and multiple affected areas were significantly different from each other (*p*\<0.001, *χ2*=19.62). Specifically, the severity of abnormal movement scores in TD patients with multiple affected areas were significantly greater than those in the other TD group (*p*\<0.001, *Z*=-3.80). The loss of movement in these two groups was also significantly different (*p*\<0.001, *Z*=-2.75). There were no significant differences in their self-awareness of abnormal movements.

According to the results of the PANSS, there were no significant differences in the positive symptom factor scores, negative symptom factor scores, general psychopathological scale factor scores and total scores between TD patients with a single affected area and those with multiple affected areas. See [Table 4](#table004){ref-type="table"}.

4. Discussion {#sec1-4}
=============

4.1 Main findings {#sec2-7}
-----------------

Four hundred and forty-eight patients with chronic schizophrenia were investigated in the present study, and forty-six of them suffered from TD (comorbidity 10.3%). There were significant differences in gender, age, total duration of illness, age of onset, the dose of antipsychotic medication (daily chlorpromazine equivalent), negative symptom factor scores and the total PANSS scores between the TD group and non-TD group. It is possible that age, gender, negative symptom factor scores and the dose of antipsychotic medication (daily chlorpromazine equivalent) are correlated with the occurrence of TD. In terms of gender, the present study showed that the occurrence of disease in males was greater than that in females, which contradicted the results of previous studies, but some scholars disagreed with the previous results as well.^\[[@ref8],[@ref9]\]^ Due to the relatively small number of women in the present study, the sample size of future studies needs to be expanded to validate the results of the present study. As for age, the mean age of patients with TD was 57.8 years old (range: 31-69) with only 3 of them being below 40 years old. This is in accordance with the results of most previous studies which indicate that being older than 40 years old could be a risk factor for TD.^\[[@ref10],[@ref11]\]^ The reason for this phenomenon is probably correlated with neurological changes in the elderly and an increase of drug concentration in the blood due to slow metabolism.^\[[@ref9]\]^

According to the results of the correlation analysis on risk factors, the duration of illness and the age of onset were not risk factors for TD. To our knowledge there have not been articles reporting on this finding. After comparing the TD group and the non-TD group, we found that patients in the TD group had significantly longer durations of illness and younger ages of onset. Since schizophrenia is a chronic illness, ^\[[@ref12]\]^ complete remission of symptoms is not often seen and in most cases patients require some form of life-long treatment or follow-up. Longer durations of illness and younger ages of onset could mean that patients also have a longer amount of time taking antipsychotics, which in turn leads to an increased risk for TD. It is therefore important for clinicians to pay special attention to those elderly patients with a long history of taking antipsychotic medication as the risk for TD may be higher in this group. Also it is recommended that patients receive regular checkups for TD, especially after an extended period of time on antipsychotic medications or for older patients as it is possible that age is a risk factor for TD.

In terms of medication, significant differences were not found between participants with single-drug use and multiple-drug use in the TD and non-TD groups. In order to standardize different medications' doses for the comparison, they were converted to chlorpromazine equivalent for all participants in the present study. After comparing both groups, we found that patients in the TD group took significantly more antipsychotic medications daily than those in the control group did. In previous studies, most scholars have written that in order to use medication safely and avoid TD, large doses of antipsychotic medication are not recommended;^\[[@ref13],[@ref14],[@ref15]\]^ however, there has been no conclusions drawn on the correlations between medication dosage and the occurrence of TD. The results of the present study show that high dosages require close attention as they may lead to TD in patients. However further study is need to look at which medications specifically increase the risk of TD, what the threshold of medication dosage is and how different medications are correlated with TD.

What is worth mentioning is that the results indicate that the negative symptom factor score in PANSS is a risk factor for TD, which means that chronic schizophrenia patients with negative symptoms as the main clinical symptoms are more likely to suffer from TD. According to the results of PANSS, the negative symptoms factor scores and the total scores of patients in the TD group are significantly greater than those in the non-TD group, which suggests that their psychotic symptoms are more severe. This result is in accordance with the studies of Miller, Gebhardt and colleagues.^\[[@ref16],[@ref17]\]^ Patients with negative symptoms as the main clinical symptoms show emotional indifference, lack of intimacy, attention deficit, lack of inner experience, lack of speech and social withdrawal. These negative symptoms in patients can cause avolition, decrease motivation to seek help and make them indifferent to reality. ^\[[@ref18]\]^ In these cases, patients may ignore changes in their health, have delusions or hallucinations, have reduced medication compliance, and even refuse treatment. All of these can present an enormous challenge to treating TD or other illnesses. Our results also showed for those TD patients with abnormal movements only 1 of the 46 patients had awareness of their abnormal movements with moderate distress. 56% of those TD patients had no self-awareness surrounding their symptoms whereas 37% had awareness but no discomfort. This phenomenon is clearly not consistent with the actual severity of patients' illness, and there is also strong evidence that chronic schizophrenia patients who suffer from TD have severe negative symptoms. Additionally, patients' lack of self-awareness, low motivation to seek treatment and not receiving timely treatment could be some of the key reasons why TD is difficult to diagnose in its early stages.

Patients with TD have various clinical symptoms affecting many different areas. After comparing the areas affected by movement disorders, we found that symptoms were mostly seen in the facial and oral areas. This finding is consistent with previous reports that the abnormal involuntary movements in head and facial areas, whose classic symptom is the mouth-tongue-cheek triple sign, are seen the most in patients with TD.^\[[@ref3],[@ref4],[@ref19]\]^ Moreover, the AIMS sub-scale scores of patients with affected facial and oral movement disorders were greater than those of patients with other affected areas, and their symptoms were more severe as well. In comparison, patients with movement disorder in their limbs were the second most severe, and patients with movement disorders in torsos were the least severe. Further explorations are needed to investigate whether facial and oral movement disorders are the first symptoms to appear in TD.

The movement disorders of patients with TD can affect a single area, but mainly we found that they affected multiple areas. The present study showed that 54.3% of patients were affected in multiple areas. For patients who had TD that affected multiple areas the mean age of onset of illness was 22.4 years old. After evaluating TD patients' abnormal movements with AIMS, we found that compared to TD patients with a single affected area, TD patients with multiple affected areas had more severe abnormal movements, which often led to a loss of mobility. Based on this, we speculate that TD patients with a young age of onset for schizophrenia are more likely to be affected in multiple areas with more severe symptoms. However, whether age of onset of schizophrenia is a risk factor for TD requires further exploration. Many scholars suggest that the age of onset is correlated with the prognosis for schizophrenia; specifically that the younger the age of onset is, the worse the prognosis is.^\[[@ref20]\]^ Hence, the correlation between the severity of TD in patients with schizophrenia and the prognosis of schizophrenia remains unclear for now.

After grouping TD patients according to their movement patterns we found that despite vastly different clinical symptoms, there were no significant differences in age, medication-taking methods, doses of antipsychotic medication, or the severity of psychotic symptoms between patients with a single affected area and patients with multiple affected areas. Additionally, even though patients with different affected patterns were significantly different in gender and the age of onset, their correlations were not statistically significant.

4.2 Limitations {#sec2-8}
---------------

The present paper tried to analyze the characteristics of movement disorders by analyzing and summarizing the clinical characteristics of patients with TD. There are several limitations to this study. (1) The sample size of the present study is relatively small, with an especially small number of women in the study. This could be expanded in the future. (2) Even though the present study discussed the two affected patterns of movement disorders in patients with TD, we did not find any relevant factors which could lead to different affected patterns. Even when patients were affected in the same area, they showed different symptoms. Therefore, in future studies with larger sample sizes we could further divide patients into groups according not only to the area affected by TD but also according to their clinical symptoms. (3) This study is cross sectional in nature and therefore no conclusions about cause and effect can be drawn. (4) In the present study, we did not find any significant differences in the methods of taking medication and the dose of antipsychotic medication between TD patients with a single affected area and those with multiple affected areas. Considering we compared different classifications of antipsychotic drugs by converting them to chlorpromazine equivalent, we were unable to discuss the correlations between the classifications of antipsychotic drugs and the different affected patterns of TD. Hence, future research could focus on the correlations between various classifications of antipsychotic drugs and the abnormal movement patterns of TD to explore the relationship between antipsychotic drug classifications and the clinical characteristics of TD.

4.3 Implications {#sec2-9}
----------------

In conclusion, the abnormal movements of patients with schizophrenia who have TD mainly occur in multiple affected areas; the severity of their abnormal movements may be greater, and their age of onset for schizophrenia may be younger. Age, the negative symptom factor score, the dose of antipsychotic medication (daily chlorpromazine equivalent) and gender are likely to be correlated with the occurrence of TD. This indicates that more caution is needed for patients with movement disorders in multiple body parts during the clinical evaluation of TD, especially for those with a young age of onset and severe negative symptoms.
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###### 

Comparisons between the TD group and the control group

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                  TD group\                                       Control group\   Statistics      *p* value                                         
                                             (n=46)                                          (n=402)                                                                            
  ------------------------------------------ ----------------------------------------------- ---------------- --------------- ------------------------------------------------- -------------------------------------------------
  Males (%)                                  36(78.26°%)                                     264(65.67%)      X^2^=4.811      0.028^[a](#table1-tfn1){ref-type="table-fn"}^     

  Mean (sd) age                              57.83(8.538)                                    44.78(12.989)    F=36.420        \<0.001^[c](#table1-tfn1){ref-type="table-fn"}^   

  Mean (sd) duration of illness              32.83(10.240)                                   26.53(6.135)     F=17.594        \<0.001^[c](#table1-tfn1){ref-type="table-fn"}^   

  Mean (sd) age of onset                     17.97(12.541)                                   24.830(5.983)    F=11.989        0.001^[b](#table1-tfn1){ref-type="table-fn"}^     

  Mean (sd) mg/d Chlorpromazine equivalent   573.07(228.554)                                 447.4(188.912)   F=10.597        0.001^[b](#table1-tfn1){ref-type="table-fn"}^     

  Patient medication use (%)                 Single-drug                                     15(32.60%)       166(41.30%)     X^2^=0.746                                        0.388

                                             Multiple-drug                                   31(67.39%)       236(58.70%)                                                       

  Mean (sd) PANSS score                      Total score                                     94.93(16.432)    85.36(20.834)   F=6.979                                           0.009^[b](#table1-tfn1){ref-type="table-fn"}^

                                             Positive symptom factor score                   21.24(6.674)     20.67(7.244)    F=0.184                                           0.669

                                             Negative symptom factor score                   32.54(6.982)     26.26(9.986)    F=13.905                                          \<0.001^[c](#table1-tfn1){ref-type="table-fn"}^

                                             General psychopathological scale factor score   41.15(11.753)    38.42(12.224)   F=1.447                                           0.231
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes: *^a^p*\<0.05, *^b^p*\<0.01, *^c^p*\<0.001.**

###### 

Analysis of risk factors for Tardive Dyskinesia

  Variable                               Partial regression coefficient   Standard error   Wald     *p* value                                         OR value   95% CI
  -------------------------------------- -------------------------------- ---------------- -------- ------------------------------------------------- ---------- --------------
  Age                                    -0.106                           0.023            21.784   \<0.001^[c](#table2-tfn1){ref-type="table-fn"}^   0.900      0.860-0.940
  Total duration of illness              -0.025                           0.150            0.028    0.867                                             0.975      0.726-1.309
  Positive and negative symptom scores   -0.125                           0.033            14.541   \<0.001^[c](#table2-tfn1){ref-type="table-fn"}^   0.882      0.828-0.941
  Age of onset                           -0.029                           0.158            0.033    0.885                                             0.972      0.713-1.324
  Chlorpromazine equivalent              -0.004                           0.001            8.294    0.004^[b](#table2-tfn1){ref-type="table-fn"}^     0.996      0.993-0.999
  Total PANSS score                      0.014                            0.021            0.468    0.494                                             1.014      0.974-1.057
  Gender                                 1.787                            0.443            16.258   \<0.001^[c](#table2-tfn1){ref-type="table-fn"}^   5.970      2.505-14.228

**Notes: *^b^p*\<0.01, *^c^p*\<0.001.**

###### 

Comparisons of areas affected by movement disorders

  Variables                       Face and mouth   Limbs         Torso         Statistics   p value
  ------------------------------- ---------------- ------------- ------------- ------------ -------------------------------------------------
  Occurrence of symptoms (n, %)   31(67.4%)        27(58.7%)     17(37%)       X^2^=9.11    0.011^[a](#table3-tfn1){ref-type="table-fn"}^
  AIMS sub-scale (points)         4.88(2.579)      3.10(1.599)   2.56(0.964)   F=9.981      \<0.001^[c](#table3-tfn1){ref-type="table-fn"}^

**Notes: *^a^p*\<0.05, *^c^p*\<0.001.**

###### 

Comparisons of TD patients with a single affected area and those with multiple affected areas

  Variables                                  Single affected area group (n=21)               Multiple affected areas group (n=25)   Statistics      *p* value                                       
  ------------------------------------------ ----------------------------------------------- -------------------------------------- --------------- ----------------------------------------------- --------------------------------------------------
  Males (%)                                  16(76.2%)                                       20(80%)                                *X^2^*=8.37     0.004^[b](#table4-tfn1){ref-type="table-fn"}^   
  Mean (sd) age                              57.10(8.596)                                    58.44(8.617)                           *F*=0.27        0.600                                           
  Mean (sd) duration of illness              24.33(11.451)                                   31.56(9.147)                           *F*=0.834       0.366                                           
  Mean (sd) age of onset                     26.88(6.240)                                    22.38(4.717)                           *F*=7.368       0.009^[b](#table4-tfn1){ref-type="table-fn"}^   
  Patient medication use (%)                 Single-drug                                     7(33.3%)                               8(32%)          *X^2^*=0.01                                     0.916
                                             Multiple-drug                                   14(66.7)                               17(68%)                                                         
  Mean (sd) mg/d Chlorpromazine equivalent   555.14(256.732)                                 588.12(206.158)                        *F*=0.23        0.631                                           
  AIMS                                       Total score (points)                            4.33(1.197)                            8.20(3.841)     *F*=19.62                                       \<0.001 ^[c](#table4-tfn1){ref-type="table-fn"}^
                                             Severity                                        15.82                                  29.96           *Z*=-3.80                                       \<0.001 ^[c](#table4-tfn1){ref-type="table-fn"}^
                                             Loss of movement ability                        17.83                                  28.26           *Z*=-2.75                                       0.005 ^[b](#table4-tfn1){ref-type="table-fn"}^
                                             Self-awareness                                  23.21                                  23.74           *Z*=-0.15                                       0.897
  Mean (sd) PANSS score                      Total score                                     94.90(16.950)                          94.96(16.336)   *F*=0.000                                       0.991
                                             Positive symptom factor score                   20.80(5.728)                           21.50(6.865)    *F*=0.002                                       0.966
                                             Negative symptom factor score                   37.94(11.956)                          38.52(13.493)   *F*=0.55                                        0.462
                                             General psychopathological scale factor score   40.24(11.912)                          41.92(11.807)   *F*=0.23                                        0.634

**Notes: The ranked data were recorded with the average rank sum; *^b^p*\<0.01, *^c^p*\<0.001.**
